The 2a trial of Rivus Pharmaceuticals' experimental metabolic booster, HU6, yielded promising results in treating High BMI individuals with Non-alcoholic Fatty Liver Disease.

Avidity Biosciences Reports Fresh Positive Results for AOC 1001, Showing Progress in Various Additional Functional Measures and Long-term Safety and Acceptability in Individuals with Type 1 Myotonic Dystrophy.

Bio-Thera Solutions has made it known that its associate company, Biogen, was recently notified by FDA about the approval of TOFIDENCE (tocilizumab-bavi) in an intravenous mixture.

Longeveron Inc. announced promising preliminary results from their Phase 2a trial with Lomecel-B™, aimed at treating mild Alzheimer’s disease.

Freeline Therapeutics reported positive preliminary results on safety, tolerability, and enzyme action from their ongoing Phase 1/2 GALILEO-1 study evaluating FLT201, their gene therapy candidate for Gaucher disease.

Nature reported on a discovery by AbbVie, the Broad Institute, and Calico Life Sciences. Their research indicates the potential of ABBV-CLS-484, an experimental drug, to act as a PTPN2/N1 phosphatase inhibitor boosting anti-cancer immunity, orally administered.

Moderna, Inc. reported encouraging preliminary outcomes from the mRNA-1083 Phase 1/2 study, a combination vaccine currently under investigation for its effect against both influenza and COVID-19.

Vedanta Biosciences recently reported the initiation of treatment for the initial participant in the COLLECTiVE202 Phase 2 investigation of VE202.

BridgeBio Pharma and National Resilience Inc., which focus on genetic diseases, cancer pharmaceuticals, and tech-driven biomanufacturing respectively, announced a partnership to develop and produce BBP-812 and BBP-631, gene therapies for Canavan disease and congenital adrenal hyperplasia.

Disc Medicine has revealed the start of a Phase 1 trial for DISC-3405 (formerly MWTX-003) with healthy participants.

Kineta, Inc., a clinical-stage biotech firm specializing in unique cancer immunotherapies, has shared updates on their ongoing Phase 1/2 clinical trial of KVA12123 for advanced solid tumor patients.

Clarity Pharmaceuticals proudly announces the initial patient dosing in their 64Cu/67Cu SAR-Bombesin Phase I/II theranostic trial for patients with metastatic castrate resistant prostate cancer.